Author:
Shoji Masaki,Ohashi Takuto,Nagase Saki,Yuri Haato,Ichihashi Kenta,Takagishi Teruhisa,Nagata Yuji,Nomura Yuki,Fukunaka Ayako,Kenjou Sae,Miyake Hatsuna,Hara Takafumi,Yoshigai Emi,Fujitani Yoshio,Sakurai Hidetoshi,dos Santos Heloísa G.,Fukada Toshiyuki,Kuzuhara Takashi
Abstract
AbstractEhlers–Danlos syndrome spondylodysplastic type 3 (EDSSPD3, OMIM 612350) is an inherited recessive connective tissue disorder that is caused by loss of function of SLC39A13/ZIP13, a zinc transporter belonging to the Slc39a/ZIP family. We previously reported that patients with EDSSPD3 harboring a homozygous loss of function mutation (c.221G > A, p.G64D) in ZIP13 exon 2 (ZIP13G64D) suffer from impaired development of bone and connective tissues, and muscular hypotonia. However, whether ZIP13 participates in the early differentiation of these cell types remains unclear. In the present study, we investigated the role of ZIP13 in myogenic differentiation using a murine myoblast cell line (C2C12) as well as patient-derived induced pluripotent stem cells (iPSCs). We found that ZIP13 gene expression was upregulated by myogenic stimulation in C2C12 cells, and its knockdown disrupted myotubular differentiation. Myocytes differentiated from iPSCs derived from patients with EDSSPD3 (EDSSPD3-iPSCs) also exhibited incomplete myogenic differentiation. Such phenotypic abnormalities of EDSSPD3-iPSC-derived myocytes were corrected by genomic editing of the pathogenic ZIP13G64D mutation. Collectively, our findings suggest the possible involvement of ZIP13 in myogenic differentiation, and that EDSSPD3-iPSCs established herein may be a promising tool to study the molecular basis underlying the clinical features caused by loss of ZIP13 function.
Funder
Japan Society for the Promotion of Science
The Nakatomi Foundation
The Uehara Memorial Foundation
Tokushima Bunri University for Educational Reform and Collaborative Research
YOKOYAMA Foundation for Clinical Pharmacology
Nagai Memorial Research Scholarship from the Pharmaceutical Society of Japan
research grant of the Princess Takamatsu Cancer Research Fund
SECOM Science and Technology Foundation
Terumo Life Science Foundation
Astellas Foundation for Research on Metabolic Disorders
The joint research program of the Institute for Molecular and Cellular Regulation, Gunma University
Publisher
Springer Science and Business Media LLC